People · Operator
Named in public records as an officer, director or promoter · active 2019–2024 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eGenesis, Inc. | — | Biotechnology | Series D+ | $265.0M | $316.4M | 2021 |
| Pyxis Oncology, Inc. | — | Pharma | Series D+ | $194.5M | $5.0B | 2019 |
| Deka Biosciences, Inc. | — | Biotechnology | Series B | $45.7M | $387.8M | 2021 |
| Azitra Inc | — | Biotechnology | Series B | $32.1M | $66.8M | 2020 |
| Immunitas Therapeutics, Inc. | — | Biotechnology | Series B | $29.1M | $716.7M | 2021 |
| Affini-T Therapeutics, Inc. | — | Biotechnology | Series B | $17.6M | $121.2M | 2024 |
Lucio Iannone at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lucio Iannone on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christoph Westphal | 2 | 8 |
| Steven Gillis | 1 | 23 |
| David Steinberg | 1 | 14 |
| Daniel Wagner | 1 | 13 |
| Christopher O'Donnell | 1 | 8 |
| Geeta Vemuri | 1 | 7 |
| PAUL SEKHRI | 1 | 7 |
| Robert Crane | 1 | 7 |
| JEFFREY GOLDBERG | 1 | 6 |
| Bob More | 1 | 6 |
| Brad Smith | 1 | 6 |
| Isaac Ciechanover | 1 | 5 |
| Arjun Goyal | 1 | 5 |
| Julie Sunderland | 1 | 5 |
| Geoff MacKay | 1 | 5 |
| Jak Knowles | 1 | 4 |
| Stella Robertson | 1 | 4 |
| Detlev Biniszkiewicz | 1 | 4 |
| John Flavin | 1 | 4 |
| Boris Nikolic | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.